Obstacles and pitfalls in the PEGylation of therapeutic proteins.
In recent years, PEGylation has become widely used as a post-production modification methodology for improving the biomedical efficacy and physicochemical properties of therapeutic proteins. Several marketed drugs that have already been in use for more than a decade have proved the applicability and safety of this technology and, with the successes already achieved, it is expected that PEGylation will be applied to other potential therapeutic proteins. The non-biodegradable nature of PEG, however, may become a limiting factor for the next generation of protein pharmaceuticals, for which use in high concentrations and in the long term is the aim, especially considering the trend for the use of branched and high molecular mass PEGs. This review addresses various obstacles and pitfalls in the production of PEGylated biopharmaceuticals, in particular, the specificity of PEGylation reactions, separation and purification issues, the analysis of inherently polydisperse PEG reagents and PEGylated products, the consistency of products and processes, and the accurate determination of pharmacokinetic properties.